JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform
September 26, 2019
Evidence-Based Diabetes Management
Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.